Manufacturer
SANOFI WINTHROP INDUSTRIE
Contents
Amiodarone HCl
Indication
Pulseless ventricular fibrillation or ventricular tachycardia, Supraventricular and ventricular arrhythmias
Instruction
Administer via rapid/slow IV Injection.
Drug interaction
Increased concentration w/ inhibitors of CYP3A4 (e.g. HIV-protease inhibitors, cimetidine). Reduced concentration w/ inducers of CYP3A4 (e.g. rifampicin, phenytoin). May induce bradycardia w/ β-blockers, Ca channel blockers, and other antiarrhythmic drugs. May increase risk of arrhythmia w/ drugs that cause hypomagnesaemia and hypokalaemia (e.g. diuretics, systemic corticosteroids). May increase concentration of ciclosporin, clonazepam, digoxin, flecainide, phenytoin, procainamide, quinidine, simvastatin, and warfarin. May affect drugs that are P-glycoprotein substrates. Potentially Fatal: May cause prolongation of QT interval w/ fluoroquinolones (e.g. moxifloxacin), antipsychotics (e.g. chlorpromazine, thioridazine, fluphenazine), lithium, TCAs (e.g. doxepin, maprotiline, amitriptyline), halofantrine, and terfenadine.
Malaysia
